Micromet to Present at the 2007 RBC Capital Markets Healthcare Conference on December 12, 2007
Posted on: Wednesday, 5 December 2007, 12:00 CST
BETHESDA, Md., Dec. 5 /PRNewswire-FirstCall/ -- Micromet, Inc. , a biopharmaceutical company focusing on the development of novel, proprietary antibody-based products for cancer, inflammation and autoimmune diseases, today announced that Dr. Christian Itin, President and Chief Executive Officer of Micromet, will be part of a panel discussion titled "Delivering On The Promise Of Antibody Therapies For Cancer" at the 2007 RBC Capital Markets Healthcare Conference in New York, on Wednesday, December 12, 2007 at 3:30pm Eastern Time (9:30pm Central European Time).
An audio webcast of Dr. Itin's remarks will be available live and accessible through Micromet's website at http://www.micromet-inc.com/, as well as a replay and download of the presentation slides following the event.
About Micromet, Inc. (http://www.micromet-inc.com/)
Micromet, Inc. is a biopharmaceutical company focusing on the development of novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases. Three of its antibodies are in clinical development. MT103 (MEDI-538), the first antibody developed using the BiTE(R) technology platform to be clinically validated in Micromet's product pipeline, is being evaluated in a phase 1 clinical trial for the treatment of patients with non- Hodgkin's lymphoma. BiTE antibodies represent a new class of antibodies that activate a patient's own cytotoxic T cells to eliminate cancer cells. Micromet is developing MT103 in collaboration with MedImmune, a subsidiary of AstraZeneca plc. The second clinical stage antibody is adecatumumab (MT201), a human monoclonal antibody targeting EpCAM expressing tumors. Adecatumumab is being developed by Micromet in collaboration with Merck Serono, a division of Merck KGaA in Darmstadt, Germany, in a phase 1b clinical trial evaluating MT201 in combination with docetaxel for the treatment of patients with metastatic breast cancer. The third clinical stage antibody is MT293 (formerly D93); also known as TRC093, a first-in-class humanized monoclonal antibody that inhibits angiogenesis and tumor cell growth by binding cleaved collagen. MT293 is licensed to TRACON Pharmaceuticals, Inc. and is being developed in a phase 1 clinical trial for the treatment of patients with cancer and age- related macular degeneration. In addition, Micromet has established a collaboration with Nycomed for the development and commercialization of MT203, Micromet's human antibody neutralizing the activity of GM-CSF, which has potential applications in the treatment of inflammatory diseases, such as rheumatoid arthritis, as well as autoimmune diseases.
Micromet, Inc.
CONTACT: Christopher Schnittker, SVP & CFO of Micromet, Inc.,+1-240-752-1421, christopher.schnittker@micromet-inc.com; Andrea tenBroek,+1-781-684-0770, micromet@schwartz-pr.com; Investors, Susan Noonan,+1-212-966-3650, susan@sanoonan.com
Web site: http://www.micromet-inc.com/
Source: PRNewswire-FirstCall
Related Articles
- Micromet Presents Update on BiTE Antibody Pipeline and Reviews Key AACR Presentations at R&D Day
- Micromet and MedImmune Initiate Treatment in Phase II Leukemia Trial
- Morphotek(R) Announces Collaboration to Facilitate Development of Human Monoclonal Antibodies for the Treatment or Prophylaxis of Infectious Disease
- Revolution Health and EmergingMed Launch Cancer Clinical Trial Matching and Referral Service
- Affymax(R) Announces Phase 2 Clinical Trial Results of Once-Per-Month Hematide(TM) for the Treatment of Anemia in Patients With Early- and End-Stage Chronic Kidney Disease
- Cell Therapeutics, Inc. (CTI) Closes PGT305 (PIONEER) Lung Cancer Clinical Trial; New PGT306 Protocol to Be Submitted to FDA By Year End
- Cell Therapeutics, Inc. (CTI) Temporarily Suspends Enrollment on PIONEER Lung Cancer Clinical Trial; Current Patients Continue to Be Treated
- Morphotek Announces Orphan Drug Status Granted for MORAb-003, A Monoclonal Antibody for the Treatment of Ovarian Cancer
- NeoRx Expands Picoplatin Lung Cancer Clinical Trial Into Selected Eastern European Countries
- 17,500 Participants Needed to Enroll in Major Colorectal Cancer Clinical Trials; CancerTrialsHelp.Org Launches QuickLink
 |
 |
User Comments (0)
RSS Feeds